No abstract

No abstract

An industrially viable, robust, and economic process is developed for Tenidap sodium and its important intermediate 5-chloro-2-oxindole-1-carboxamide. Use of inorganic cyanates, in place of organic isocyanates, makes the process simple and commercially viable. The advantage of using acetic anhydride and sodium acetate over reported reagents such as trifluoroacetic acid and its anhydride on industrial scale is described. Drastic reduction of DMAP in the final step and overall improvement of yields makes the process economical. sodium (1) (Figure 1), are for the treatment of rheumatoid arthritis 1 and osteoarthritis 2 . Tenidap is an inhibitor of prostaglandin 3 and interleukin-1 4 production in the body. It inhibits both the enzymes cycloxygenase and 5-lypoxygenase, 5 which convert arachidonic acid into prostaglandin and leukotrienes 3 , and exhibits superior activity compared to other nonsteroidal antiinflammatory drugs (NSAIDs) such as naproxen, 6 piroxicam, 7 diclofenac sodium, 8 indomethacin, 9 and so forth, currently available in the market. Tenidap sodium has not been launched in the market because of toxic effects found in clinical trials. † DRF publication No. 99.

No abstract

ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.